128 related articles for article (PubMed ID: 33839039)
21.
Su X; Zhang J; Mouawad R; Compérat E; Rouprêt M; Allanic F; Parra J; Bitker MO; Thompson EJ; Gowrishankar B; Houldsworth J; Weinstein JN; Tost J; Broom BM; Khayat D; Spano JP; Tannir NM; Malouf GG
Cancer Res; 2017 Sep; 77(18):4835-4845. PubMed ID: 28754676
[TBL] [Abstract][Full Text] [Related]
22. High selectivity of PI3Kβ inhibitors in SETD2-mutated renal clear cell carcinoma.
Wang J; Wen J; Yi R; Liu F; Zhou J; Liu G; Li Q; Yang Z; Su X
J BUON; 2015; 20(5):1267-75. PubMed ID: 26537074
[TBL] [Abstract][Full Text] [Related]
23. SETD2 loss perturbs the kidney cancer epigenetic landscape to promote metastasis and engenders actionable dependencies on histone chaperone complexes.
Xie Y; Sahin M; Sinha S; Wang Y; Nargund AM; Lyu Y; Han S; Dong Y; Hsieh JJ; Leslie CS; Cheng EH
Nat Cancer; 2022 Feb; 3(2):188-202. PubMed ID: 35115713
[TBL] [Abstract][Full Text] [Related]
24. Immunohistochemical negative expression of ezrin predicts poor prognosis in clear cell renal cell carcinoma.
Ferrari MVO; da Costa WH; Matushita MAM; Meduna RR; Brazao ES; Bezerra SM; da Cunha IW; Zequi SC
Urol Oncol; 2020 Mar; 38(3):75.e1-75.e7. PubMed ID: 31648868
[TBL] [Abstract][Full Text] [Related]
25. Prognostic Value of a Long Non-coding RNA Signature in Localized Clear Cell Renal Cell Carcinoma.
Qu L; Wang ZL; Chen Q; Li YM; He HW; Hsieh JJ; Xue S; Wu ZJ; Liu B; Tang H; Xu XF; Xu F; Wang J; Bao Y; Wang AB; Wang D; Yi XM; Zhou ZK; Shi CJ; Zhong K; Sheng ZC; Zhou YL; Jiang J; Chu XY; He J; Ge JP; Zhang ZY; Zhou WQ; Chen C; Yang JH; Sun YH; Wang LH
Eur Urol; 2018 Dec; 74(6):756-763. PubMed ID: 30143382
[TBL] [Abstract][Full Text] [Related]
26. Aberrant promoter hypermethylation of PBRM1, BAP1, SETD2, KDM6A and other chromatin-modifying genes is absent or rare in clear cell RCC.
Ibragimova I; Maradeo ME; Dulaimi E; Cairns P
Epigenetics; 2013 May; 8(5):486-93. PubMed ID: 23644518
[TBL] [Abstract][Full Text] [Related]
27. SETD2 loss-of-function promotes renal cancer branched evolution through replication stress and impaired DNA repair.
Kanu N; Grönroos E; Martinez P; Burrell RA; Yi Goh X; Bartkova J; Maya-Mendoza A; Mistrík M; Rowan AJ; Patel H; Rabinowitz A; East P; Wilson G; Santos CR; McGranahan N; Gulati S; Gerlinger M; Birkbak NJ; Joshi T; Alexandrov LB; Stratton MR; Powles T; Matthews N; Bates PA; Stewart A; Szallasi Z; Larkin J; Bartek J; Swanton C
Oncogene; 2015 Nov; 34(46):5699-708. PubMed ID: 25728682
[TBL] [Abstract][Full Text] [Related]
28. TPX2 as a prognostic indicator and potential therapeutic target in clear cell renal cell carcinoma.
Glaser ZA; Love HD; Guo S; Gellert L; Chang SS; Herrell SD; Barocas DA; Penson DF; Cookson MS; Clark PE
Urol Oncol; 2017 May; 35(5):286-293. PubMed ID: 28108243
[TBL] [Abstract][Full Text] [Related]
29.
Chiang YC; Park IY; Terzo EA; Tripathi DN; Mason FM; Fahey CC; Karki M; Shuster CB; Sohn BH; Chowdhury P; Powell RT; Ohi R; Tsai YS; de Cubas AA; Khan A; Davis IJ; Strahl BD; Parker JS; Dere R; Walker CL; Rathmell WK
Cancer Res; 2018 Jun; 78(12):3135-3146. PubMed ID: 29724720
[TBL] [Abstract][Full Text] [Related]
30. Higher expression of topoisomerase II alpha is an independent marker of increased risk of cancer-specific death in patients with clear cell renal cell carcinoma.
Parker AS; Eckel-Passow JE; Serie D; Hilton T; Parasramka M; Joseph RW; Wu KJ; Cheville JC; Leibovich BC
Eur Urol; 2014 Nov; 66(5):929-35. PubMed ID: 24388441
[TBL] [Abstract][Full Text] [Related]
31. SETD2 Deficiency Confers Sensitivity to Dual Inhibition of DNA Methylation and PARP in Kidney Cancer.
Zhou X; Sekino Y; Li HT; Fu G; Yang Z; Zhao S; Gujar H; Zu X; Weisenberger DJ; Gill IS; Tulpule V; D'souza A; Quinn DI; Han B; Liang G
Cancer Res; 2023 Nov; 83(22):3813-3826. PubMed ID: 37695044
[TBL] [Abstract][Full Text] [Related]
32. Low Expression of Mucin-4 Predicts Poor Prognosis in Patients With Clear-Cell Renal Cell Carcinoma.
Fu H; Liu Y; Xu L; Chang Y; Zhou L; Zhang W; Yang Y; Xu J
Medicine (Baltimore); 2016 Apr; 95(17):e3225. PubMed ID: 27124015
[TBL] [Abstract][Full Text] [Related]
33. High expression of Mucin13 associates with grimmer postoperative prognosis of patients with non-metastatic clear-cell renal cell carcinoma.
Xu Z; Liu Y; Yang Y; Wang J; Zhang G; Liu Z; Fu H; Wang Z; Liu H; Xu J
Oncotarget; 2017 Jan; 8(5):7548-7558. PubMed ID: 27911274
[TBL] [Abstract][Full Text] [Related]
34. The chemokine receptor CXCR3 is an independent prognostic factor in patients with localized clear cell renal cell carcinoma.
Klatte T; Seligson DB; Leppert JT; Riggs SB; Yu H; Zomorodian N; Kabbinavar FF; Strieter RM; Belldegrun AS; Pantuck AJ
J Urol; 2008 Jan; 179(1):61-6. PubMed ID: 17997430
[TBL] [Abstract][Full Text] [Related]
35. Identification and validation of novel prognostic markers in Renal Cell Carcinoma.
Rabjerg M
Dan Med J; 2017 Oct; 64(10):. PubMed ID: 28975890
[TBL] [Abstract][Full Text] [Related]
36. Does chromophobe renal cell carcinoma have better survival than clear cell renal cell carcinoma? A clinical-based cohort study and meta-analysis.
Jiang HM; Wei JH; Zhang ZL; Fang Y; Zhou BF; Chen ZH; Lu J; Liao B; Zhou FJ; Luo JH; Chen W
Int Urol Nephrol; 2016 Feb; 48(2):191-9. PubMed ID: 26589610
[TBL] [Abstract][Full Text] [Related]
37. Integrative radiogenomics analysis for predicting molecular features and survival in clear cell renal cell carcinoma.
Zeng H; Chen L; Wang M; Luo Y; Huang Y; Ma X
Aging (Albany NY); 2021 Mar; 13(7):9960-9975. PubMed ID: 33795526
[TBL] [Abstract][Full Text] [Related]
38. Identification of Prognostic Biomarkers for Clear Cell Renal Cell Carcinoma (ccRCC) by Transcriptomics.
Zhang S; Xu X; Wang Y; Zhu Y; Wang J; Wang H; Guo J
Ann Clin Lab Sci; 2021 Sep; 51(5):597-608. PubMed ID: 34686501
[TBL] [Abstract][Full Text] [Related]
39. Computational analysis of the mutations in BAP1, PBRM1 and SETD2 genes reveals the impaired molecular processes in renal cell carcinoma.
Piva F; Giulietti M; Occhipinti G; Santoni M; Massari F; Sotte V; Iacovelli R; Burattini L; Santini D; Montironi R; Cascinu S; Principato G
Oncotarget; 2015 Oct; 6(31):32161-8. PubMed ID: 26452128
[TBL] [Abstract][Full Text] [Related]
40. The roles of chromatin-remodelers and epigenetic modifiers in kidney cancer.
Liao L; Testa JR; Yang H
Cancer Genet; 2015 May; 208(5):206-14. PubMed ID: 25873528
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]